ValuentumAd

Official PayPal Seal














Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
May 17, 2018
Master Limited Partnership Simplifications on the Rise
With the announcement of three separate master limited partnership simplification transactions on May 17 alone, we must revisit our thesis that the business structure may not be in it for the long haul.
May 17, 2018
Cisco’s Long Term Remains Bright; Not Worried
Image Source: Ashwin Kumar. Cisco’s fiscal third quarter results came in mostly as expected, but shares faced selling pressure following the release as the company’s operating margin was squeezed in the quarter. We still like Cisco a lot and are not concerned about the market’s tunnel vision. The company’s free cash flow performance and a huge net cash position are hard not to like. We’re not worried.
May 17, 2018
Has Macy’s Found Its Winning Formula? J.C. Penney Might Be a $0
Shares of Macy’s surged following its fiscal first quarter report May 16 as the department store beat estimates and raised its full-year guidance. That said, we continue to be cautious on the long-term prospects of big box retailers and the department stores, in particular. You won’t see us adding any department store to the simulated newsletter portfolios. J.C. Penney might be a $0 during the next downturn, whenever that comes.
May 17, 2018
Home Depot's First-Quarter A Little Light; Long-term Still Bright
Home Depot’s fiscal 2018 first quarter results came in short of expectations largely due to adverse weather conditions in many parts of the country, but the company reiterated its full-year guidance in a vote of confidence from management.
May 16, 2018
Sports Betting Legalized; Churchill Downs Has Leg Up on Rivals
In a landmark decision, the US Supreme Court ruled that states could legalize sports betting. We expect this to be a positive catalyst for several gambling-related equities, and many are moving fast to capitalize on the development. We’re taking a long-term view on potential ramifications and are not jumping head-first into any potential opportunities…yet.
May 15, 2018
Disney’s Top Line Growing as It Leverages Film Successes
Image Source: David Holt. Media giant Disney has been executing well of late as it leverages its successful content into a broader scope of entertainment, but competition may be heating up related to its pending acquisition of Twenty-First Century Fox’s media assets.
May 14, 2018
Top 5 Burning Questions on Gilead Sciences
Image Source: Gilead Lab. We felt answers to a few burning questions pertaining to the abysmal first-quarter 2018 earnings release by Gilead Sciences would be of value to our readers. We are not in the least bit impressed by the earnings print, but we feel patience may be well rewarded. The Questions: 1. When will the decline in the Hepatitis C franchise abate? 2. Which new product will drive future revenue growth? 3. Will Cytokine Release Syndrome sink the potential of Yescarta? 4. How durable is Gilead's HIV franchise? 5. What else is in Gilead's pipeline?
May 11, 2018
Dividend Increases/Decreases for the Week Ending May 11
Let's take a look at companies that raised/lowered their dividend this week.
May 10, 2018
Soft Guidance Weighs on Booking Holdings Despite Solid First Quarter
Image Source: Luca Conti. You may have read this sentiment before: shares of Booking Holdings, formerly Priceline, are facing pressure following a solid quarterly report as management continued its habit of issuing conservative quarterly guidance.
May 10, 2018
Generic Drug Deflation Continues to Hamper Cardinal Health and AmerisourceBergen
Image Source: Aaron Fulkerson. A severe case of rampant generic drug deflation continues to hamper the share prices of Cardinal Health and AmerisourceBergen. We are monitoring the drug deflation numbers posted by the drug wholesalers as a key gauge of the investment merits of the group.



The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.